Bioequivalence of HX575 (Recombinant Human Epoetin Alfa) and a Comparator Epoetin Alfa After Multiple Subcutaneous Administrations

Pharmacology - Switzerland
doi 10.1159/000189027
Full Text
Abstract

Available in full text

Date
Authors
Publisher

S. Karger AG

Related search

A Comparison of the Bioequivalence of Two Formulations of Epoetin Alfa After Subcutaneous Injection

British Journal of Clinical Pharmacology
Pharmacology
2004English

Epoetin Alfa: Future Directions and Future Research

Oncologist
Cancer ResearchMedicineOncology
2004English

Comparison of the Therapeutic Efficacy of Epoetin Beta and Epoetin Alfa in Maintenance Phase Hemodialysis Patients

Renal Failure
MedicineNephrologyCritical CareIntensive Care Medicine
2011English

Human Choriogonadotropin and Epoetin Alfa in Acute Ischemic Stroke Patients (REGENESIS-LED Trial)

International Journal of Stroke
Neurology
2014English

Strategies for the Use of Epoetin Alfa in Breast Cancer Patients

Oncologist
Cancer ResearchMedicineOncology
1998English

Perbandingan Kualitas Hidup Pasien Yang Menjalani Hemodialisis Dengan Terapi Epoetin Alfa Dan Epoetin Beta Di RS PKU Muhammadiyah Yogyakarta

Jurnal Farmasi (Journal of Pharmacy)
2019English

Comparative Safety of Originator and Biosimilar Epoetin Alfa Drugs: An Observational Prospective Multicenter Study

BioDrugs
MedicineBiotechnologyPharmacology
2018English

Epoetin Alfa in Platinum-Treated Ovarian Cancer Patients: Results of a Multinational, Multicentre, Randomised Trial

British Journal of Cancer
Cancer ResearchOncology
2006English

Budget Impact Analysis of Darbepoetin Alfa Every 3 Weeks Versus Epoetin Alfa Every Week for Cancer Patients Receiving Chemotherapy From a Us Payer's Perspective

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy